Get the Stockscreener App
4.91
1.45%
0.07
Envveno Medical Corporation stock is traded at $4.91, with a volume of 17,808.
It is up +1.45% in the last 24 hours and up +20.34% over the past month.
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.
See More
Previous Close:
$4.84
Open:
$4.9
24h Volume:
17,808
Relative Volume:
0.16
Market Cap:
$86.10M
Revenue:
-
Net Income/Loss:
$-24.05M
P/E Ratio:
-2.2837
EPS:
-2.15
Net Cash Flow:
$-17.78M
1W Performance:
+14.99%
1M Performance:
+20.34%
6M Performance:
+40.69%
1Y Performance:
-13.71%
1-Day Range:
$4.77
$4.97
1-Week Range:
$4.21
$5.62
52-Week Range:
$2.0278
$5.915
Envveno Medical Corporation Stock (NVNO) Company Profile
Name
Envveno Medical Corporation
Sector
Industry
Phone
949-261-2900
Address
70 DOPPLER, IRVINE
Compare NVNO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVNO
Envveno Medical Corporation
|
4.91 | 72.34M | 0 | -24.05M | -17.78M | -2.15 |
|
ABT
Abbott Laboratories
|
123.44 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.43 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
393.82 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.06 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.75 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Envveno Medical Corporation Stock (NVNO) Latest News
enVVeno Medical Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference - Lohud
What analysts say about enVVeno Medical Corporation stockExplosive wealth accumulation - Autocar Professional
Is enVVeno Medical Corporation a good long term investmentBreakout portfolio performance - jammulinksnews.com
enVVeno Medical Corporation Stock Analysis and ForecastRemarkable growth - jammulinksnews.com
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live - Corpus Christi Caller-Times
iTolerance, Inc. Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference - Bergen Record
Inside enVVeno Medical: CEO Shares Breakthrough Vision for Deep Venous Disease Treatment Revolution - Stock Titan
What makes enVVeno Medical Corporation stock price move sharplyPrecision Entry Strategy - Newser
What drives enVVeno Medical Corporation stock priceAccelerated earnings growth - Autocar Professional
JTC Team Announces Participating Line Up for the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference - Pocono Record
Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth - simplywall.st
How enVVeno Medical Corporation stock performs during market volatilityHigh Reward Risk Balanced Trading - Newser
Why enVVeno Medical Corporation stock attracts strong analyst attentionLow Risk Profit Ideas - Newser
Envoy Medical and enVVeno: Navigating Near-Term Turbulence for Long-Term Medical Device Dominance - AInvest
Jane Street Group LLC Acquires New Shares in enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
enVVeno Medical (NVNO) Shares Update on Promising Two-Year VenoV - GuruFocus
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting - The Oklahoman
enVVeno Medical (NVNO) Showcases Promising Two-Year Data for Ven - GuruFocus
enVVeno Medical (NVNO) Shares Update on Promising Two-Year VenoValve Trial Results | NVNO Stock News - GuruFocus
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pi - GuruFocus
enVVeno Medical announces two-year data from VenoValve pivotal study - TipRanks
enVVeno Medical announces interim two-year follow-up data on VenoValve trial - TipRanks
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting | NVNO Stock News - GuruFocus
VenoValve Shows 83% Success Rate in 2-Year Trial Data, FDA Decision Due 2025 | NVNO Stock News - Stock Titan
enVVeno Medical Corporation (NASDAQ:NVNO) Short Interest Up 19.4% in May - Defense World
NVNBWForm FWPFiling under Securities Act Rules 163/433 of free writing prospectuses - mx.advfn.com
Northern Trust Corp Raises Holdings in enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
enVVeno Medical surges 70% following InvestingPro’s Fair Value signal By Investing.com - Investing.com India
enVVeno Medical appoints Jennifer Bright as financial chief - MSN
enVVeno Medical Appoints New Chief Financial Officer - TipRanks
Envveno Medical Corporation Stock (NVNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):